SCHEMBL7609822

SCHEMBL7609822

CNC(=O)C(NC(=O)C[C@@H](NC(=O)OC(C)(C)C)C(=O)OCc1ccccc1)C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.51
PSMB5 P28074 1/20 0.49
KLK5 Q9Y337 3/20 0.49
KLK7 P49862 1/20 0.49
MMP3 P08254 3/20 0.48
MMP1 P03956 2/20 0.48
MMP9 P14780 2/20 0.48
MMP8 P22894 1/20 0.48
CTSS P25774 3/20 0.48
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
CTSK P43235 1/20 0.47
TACR1 P25103 1/20 0.46
CACNA1B Q00975 2/20 0.46
MMP2 P08253 4/20 0.46
MMP14 P50281 1/20 0.46
PPARG P37231 1/20 0.46
SYK P43405 1/20 0.46
MMP13 P45452 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609826 1.00 PPARA (0.51) PPARAPSMB5KLK5KLK7MMP3
SCHEMBL7895767 0.86 MMP3 (0.50) PSMB5MMP3MMP1MMP9MMP8
SCHEMBL7895770 0.86 MMP3 (0.50) PSMB5MMP3MMP1MMP9MMP8
SCHEMBL7406802 0.85 KLK7 (0.54) PPARAPSMB5KLK5KLK7MMP3
SCHEMBL7410104 0.85 KLK7 (0.54) PPARAPSMB5KLK5KLK7MMP3
SCHEMBL18813654 0.82 KLK5 (0.54) PPARAKLK5KLK7CTSSCTSL
SCHEMBL5033775 0.82 PPARA (0.58) PPARAKLK5KLK7CTSSCTSL
SCHEMBL3004720 0.82 PPARA (0.58) PPARAKLK5KLK7CTSSCTSL
SCHEMBL1093029 0.82 PPARA (0.58) PPARAKLK5KLK7CTSSCTSL
SCHEMBL30687368 0.81 KLK5 (0.53) PPARAKLK5KLK7CTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use BENDER STEVEN L (US) 2002-02-14 US disclosed
US-6306892-B1 ENZYME INHIBITORS HETEROCYCLIC AMIDES AGOURON PHARMACEUTICALS, INC. 2001-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use MMP9, MMP2, MMP3 PPARA 4606/4885PSMB5 1205/4885KLK5 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.